Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) shares traded down 15.2% on Thursday . The stock traded as low as GBX 192 ($2.44) and last traded at GBX 201.88 ($2.57). 138,103 shares were traded during trading, an increase of 418% from the average session volume of 26,667 shares. The stock had previously closed at GBX 238 ($3.02).
Faron Pharmaceuticals Oy Stock Performance
The company has a debt-to-equity ratio of 121.51, a current ratio of 0.59 and a quick ratio of 1.09. The company’s 50-day moving average price is GBX 154.64 and its two-hundred day moving average price is GBX 222.80. The company has a market capitalization of £141.14 million, a price-to-earnings ratio of -466.20 and a beta of -0.13.
Faron Pharmaceuticals Oy Company Profile
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation.
Read More
- Five stocks we like better than Faron Pharmaceuticals Oy
- How to Use the MarketBeat Excel Dividend Calculator
- What is a Short Call Butterfly Spread? Explanation with Examples
- 3 Best Fintech Stocks for a Portfolio Boost
- First Quarter Wrap-Up Reveals Retail’s Shifting Sands
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Williams-Sonoma Stock Forecast to Hit $500? Here’s How
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
